Genetron aims to radically improve the accessibility, affordability, and accuracy of early detection
solutions for you and your family. Expanding from single cancer types to multiple cancer types, R&D
breakthroughs and product commercialization must not only meet clinical needs, but also elevate service
standards—only then can we reduce the mortality rate of cancer and foster lasting, generational impact.
LIVER CANCER, THE FIRST BREAKTHROUGH
In March 2019, Genetron—in collaboration with the National Cancer Center (PRC) and the Cancer Hospital
of the China Academy of Medical Sciences—published the research breakthroughs for a prospective cohort
for early screening of liver cancer in the Proceedings of the National Academy of Sciences (PNAS).
In August 2020, the Ministry of Science and Technology (PRC) launched a
national R&D project for early cancer screening, selecting Genetron Health to participate in developing
key technologies for the early detection of multiple cancer types
FINDING EARLY LIVER CANCER AT THE ASYMPTOMATIC
STAGE, WHEN IT CAN BE
Owing to its superior clinical performance over the current
(i.e. Type-B ultrasound & AFP protein detection), Genetron Health's liver cancer early screening technology
HCCscreenTM received the "Breakthrough Device Designation" from the US FDA.1
1 Based on results from the prospective cohort study using Genetron's high-throughput sequencing (NGS)
Using HCCscreen™️, Genetron Health offers product distribution and service coverage across three major
PUBLIC HEALTH PROGRAM
A “Liver Cancer Early SCREENING Comprehensive Prevention Program,” launched in
collaboration with the National Cancer Center and Wuxi Municipality Huishan District Government.
An exclusive strategic cooperation with CTTQ Pharma to jointly service the hospital
market, providing precision oncology solutions to high-risk clinical patients with liver disease.
An exclusive strategic cooperation with iKang Group to provide early screening
products for the general population, covering over 150 locations across all of China.